Hee Joon Bae1, Omar Mian2, Dhananjay Vaidya3, Theodore L DeWeese1, Daniel Y Song4. 1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. 2. Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, Ohio. 3. Department of Oncology-Biostatistics and Bioinformatics Division, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. Electronic address: dsong2@jhmi.edu.
Abstract
INTRODUCTION: Prostate hypertrophy, median lobe hypertrophy, and pubic arch interference (PAI) are relative contraindications to brachytherapy because of potential morbidity and technical considerations. GnRH analogs or non-steroidal anti-androgens are currently utilized to achieve prostatic downsizing prior to brachytherapy. However, such agents have been associated with effects on body habitus, metabolism, and quality of life. In contrast, 5-alpha reductase inhibitors (5-ARI) are far less frequently associated with these morbidities. METHODS AND MATERIALS: Patients with large gland size, median lobe hypertrophy, or PAI were offered 5-ARI therapy. Repeat transrectal ultrasound was performed at 3 or 4 months, followed by brachytherapy if resolution was achieved. If downsizing was inadequate, patients were offered continuation of 5-ARI for additional 3 months, gonadotropin-releasing hormone analog (GnRH) agonist or antiandrogen therapy, or other curative treatment. RESULTS: Of 59 patients with follow-up available, 42 (71%) were deemed to have adequate downsizing; 37 (63%) after 3 to 4 months of 5-ARI and 5 (8%) after 7 to 8 months. Seventeen patients (29%) received other treatments because of inadequate effect. Median volume reduction was 20%. Of 41 patients undergoing brachytherapy, 4 (9.7%) required temporary catheterization because of obstruction. Median follow-up after implantation was 25 months (range, 1-64). Median time for return to International Prostate Symptom Score ≤5 of baseline score was 7 months (interquartile ratio, 6-13). All but 1 patient who received brachytherapy remain biochemically controlled. CONCLUSION: 5-ARI monotherapy is an alternative for downsizing in patients with hypertrophy or PAI, with more than 70% achieving adequate downsizing without use of GnRH analogs or antiandrogens. Patients who received brachytherapy experienced typical rates of postimplant urinary morbidity.
INTRODUCTION:Prostate hypertrophy, median lobe hypertrophy, and pubic arch interference (PAI) are relative contraindications to brachytherapy because of potential morbidity and technical considerations. GnRH analogs or non-steroidal anti-androgens are currently utilized to achieve prostatic downsizing prior to brachytherapy. However, such agents have been associated with effects on body habitus, metabolism, and quality of life. In contrast, 5-alpha reductase inhibitors (5-ARI) are far less frequently associated with these morbidities. METHODS AND MATERIALS: Patients with large gland size, median lobe hypertrophy, or PAI were offered 5-ARI therapy. Repeat transrectal ultrasound was performed at 3 or 4 months, followed by brachytherapy if resolution was achieved. If downsizing was inadequate, patients were offered continuation of 5-ARI for additional 3 months, gonadotropin-releasing hormone analog (GnRH) agonist or antiandrogen therapy, or other curative treatment. RESULTS: Of 59 patients with follow-up available, 42 (71%) were deemed to have adequate downsizing; 37 (63%) after 3 to 4 months of 5-ARI and 5 (8%) after 7 to 8 months. Seventeen patients (29%) received other treatments because of inadequate effect. Median volume reduction was 20%. Of 41 patients undergoing brachytherapy, 4 (9.7%) required temporary catheterization because of obstruction. Median follow-up after implantation was 25 months (range, 1-64). Median time for return to International Prostate Symptom Score ≤5 of baseline score was 7 months (interquartile ratio, 6-13). All but 1 patient who received brachytherapy remain biochemically controlled. CONCLUSION: 5-ARI monotherapy is an alternative for downsizing in patients with hypertrophy or PAI, with more than 70% achieving adequate downsizing without use of GnRH analogs or antiandrogens. Patients who received brachytherapy experienced typical rates of postimplant urinary morbidity.
Authors: Carolyn A Allan; Veronica R Collins; Mark Frydenberg; Robert I McLachlan; Kati L Matthiesson Journal: Endocr Relat Cancer Date: 2014-05-28 Impact factor: 5.678
Authors: Joshua H Petit; Clifford Gluck; W S Kiger; D Laury Henry; Carol Karasiewicz; James Talcott; Solomon Berg; Edward Holupka; Irving Kaplan Journal: Urol Oncol Date: 2008-01-08 Impact factor: 3.498
Authors: Akash Nanda; Ming-Hui Chen; Brian J Moran; Michelle H Braccioforte; Daniel Dosoretz; Sharon Salenius; Michael Katin; Rudi Ross; Anthony V D'Amico Journal: Eur Urol Date: 2012-09-07 Impact factor: 20.096
Authors: Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder Journal: BJU Int Date: 2008-12 Impact factor: 5.588
Authors: Sarah N Hopmans; Wilhelmina C M Duivenvoorden; Geoff H Werstuck; Laurence Klotz; Jehonathan H Pinthus Journal: Urol Oncol Date: 2014-09-18 Impact factor: 3.498
Authors: Anders Fagerlund; Luigi Cormio; Lina Palangi; Richard Lewin; Fabio Santanelli di Pompeo; Anna Elander; Gennaro Selvaggi Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240